Table of Contents Author Guidelines Submit a Manuscript
Cardiovascular Therapeutics
Volume 2019, Article ID 7836527, 8 pages
https://doi.org/10.1155/2019/7836527
Clinical Study

Comparison of the Effect of Fimasartan versus Valsartan on Blood Pressure Variability in Acute Ischemic Stroke: A Double-Blind Randomized Trial

1Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
2Department of Biomedical Engineering, Gachon University of Medicine and Science, Incheon, Republic of Korea

Correspondence should be addressed to Yeong Bae Lee; moc.liamg@eeleabgnoey

Received 20 February 2019; Revised 15 April 2019; Accepted 24 April 2019; Published 2 June 2019

Academic Editor: Brian Tomlinson

Copyright © 2019 Dong Hoon Shin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. James, S. Oparil, B. L. Carter et al., “2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8),” Journal of the American Medical Association, vol. 311, no. 5, pp. 507–520, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Kawai, M. Ohishi, K. Kamide et al., “The impact of visit-to-visit variability in blood pressure on renal function,” Hypertension Research, vol. 35, no. 2, pp. 239–243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. P. M. Rothwell, S. C. Howard, E. Dolan et al., “Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension,” The Lancet, vol. 375, no. 9718, pp. 895–905, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Suchy-Dicey, E. R. Wallace, S. V. E. Mitchell et al., “Blood pressure variability and the risk of all-cause mortality, incident myocardial infarction, and incident stroke in the cardiovascular health study,” American Journal of Hypertension, vol. 26, no. 10, pp. 1210–1217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Conway, N. Boon, C. Davies, J. V. Jones, and P. Sleight, “Neural and humoral mechanisms involved in blood pressure variability,” Journal of Hypertension, vol. 2, no. 2, pp. 203–208, 1984. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Mancia, G. Parati, G. Pomidossi, R. Casadei, M. Di Rienzo, and A. Zanchetti, “Arterial baroreflexes and blood pressure and heart rate variabilities in humans,” Hypertension, vol. 8, no. 2, pp. 147–153, 1986. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Okada, M. Fukui, M. Tanaka et al., “Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes,” Atherosclerosis, vol. 220, no. 1, pp. 155–159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Kikuya, T. Ohkubo, H. Metoki et al., “Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: The Ohasama Study,” Hypertension, vol. 52, no. 6, pp. 1045–1050, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. P. M. Rothwell, “Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension,” The Lancet, vol. 375, no. 9718, pp. 938–948, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Frattola, G. Parati, C. Cuspidi, F. Albini, and G. Mancia, “Prognostic value of 24-hour blood pressure variability,” Journal of Hypertension, vol. 11, no. 10, pp. 1133–1137, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Kikuya, A. Hozawa, T. Ohokubo et al., “Prognostic significance of blood pressure and heart rate variabilities: the Ohasama Study,” Hypertension, vol. 36, no. 5, pp. 901–906, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Pringle, C. Phillips, L. Thijs et al., “Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population,” Journal of Hypertension, vol. 21, no. 12, pp. 2251–2257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Verdecchia, F. Angeli, R. Gattobigio, C. Rapicetta, and G. Reboldi, “Impact of Blood Pressure Variability on Cardiac and Cerebrovascular Complications in Hypertension,” American Journal of Hypertension, vol. 20, no. 2, pp. 154–161, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Muntner, D. Shimbo, M. Tonelli, K. Reynolds, D. K. Arnett, and S. Oparil, “The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994,” Hypertension, vol. 57, no. 2, pp. 160–166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Webb, U. Fischer, Z. Mehta, and P. M. Rothwell, “Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis,” The Lancet, vol. 375, no. 9718, pp. 906–915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. S.-I. Masuda, K. Tamura, H. Wakui et al., “Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy,” Hypertension Research, vol. 32, no. 11, pp. 950–955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Parati, E. Dolan, L. Ley, and H. Schumacher, “Impact of antihypertensive combination and monotreatments on blood pressure variability: Assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database,” Journal of Hypertension, vol. 32, no. 6, pp. 1326–1333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Yoshida, H. Akasaka, S. Saitoh, K. Shimamoto, and T. Miura, “Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy,” Hypertension Research, vol. 37, no. 3, pp. 225–231, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J. B. Park, K. Sung, S. Kang, and E. J. Cho, “Safety and efficacy of fimasartan in patients with arterial hypertension (safe-kanarb study),” American Journal of Cardiovascular Drugs, vol. 13, no. 1, pp. 47–56, 2013. View at Publisher · View at Google Scholar
  20. H.-Y. Lee and B.-H. Oh, “Fimasartan: a new angiotensin receptor blocker,” Drugs, vol. 76, no. 10, pp. 1015–1022, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Eguchi, Y. Imaizumi, T. Kaihara, S. Hoshide, and K. Kario, “Comparison of valsartan and amlodipine on ambulatory blood pressure variability in hypertensive patients,” Clinical and Experimental Hypertension, vol. 38, no. 8, pp. 721–724, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. M. R. Law, J. K. Morris, and N. J. Wald, “Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies,” British Medical Journal, vol. 338, Article ID b1665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. H. Katsanos, A. Filippatou, E. Manios et al., “Blood Pressure Reduction and Secondary Stroke Prevention,” Hypertension, vol. 69, no. 1, pp. 171–179, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Rashid, J. Leonardi-Bee, and P. Bath, “Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review,” Stroke, vol. 34, no. 11, pp. 2741–2748, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Madden, A. M. O'Flynn, A. P. Fitzgerald, and P. M. Kearney, “Correlation between short-term blood pressure variability and left-ventricular mass index: A meta-analysis,” Hypertension Research, vol. 39, no. 3, pp. 171–177, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. L. J. Mena, V. G. Felix, J. D. Melgarejo, and G. E. Maestre, “24-Hour blood pressure variability assessed by average real variability: A systematic review and meta-analysis,” Journal of the American Heart Association, vol. 6, no. 10, 2017. View at Google Scholar · View at Scopus
  27. G. Parati, J. E. Ochoa, C. Lombardi, and G. Bilo, “Assessment and management of blood-pressure variability,” Nature Reviews Cardiology, vol. 10, no. 3, pp. 143–155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Ohkubo, A. Hozawa, J. Yamaguchi et al., “Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The ohasama study,” Journal of Hypertension, vol. 20, no. 11, pp. 2183–2189, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. L. S. Manning, P. M. Rothwell, J. F. Potter, and T. G. Robinson, “Prognostic significance of short-term blood pressure variability in acute stroke: systematic review,” Stroke, vol. 46, no. 9, pp. 2482–2490, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Kakaletsis, G. Ntaios, H. Milionis et al., “Prognostic value of 24-h ABPM in acute ischemic stroke for short-, medium-, and long-term outcome: A systematic review and meta-analysis,” International Journal of Stroke, vol. 10, no. 7, pp. 1000–1007, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Delgado-Mederos and C. A. Molina, “Prognostic significance of blood pressure variability after thrombolysis in acute stroke,” Neurology, vol. 72, no. 20, pp. 1792-1793, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. H. S. Weintraub and J. Basile, “The pleiotropic effects of antihypertensive agents: do they account for additional cardiovascular benefit beyond BP reduction?” Southern Medical Journal, vol. 101, no. 8, pp. 818–823, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. H. Krieger, A. Di Lorenzo, C. Teutsch, K. Kauser, and W. C. Sessa, “Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice,” Laboratory Investigation, vol. 90, no. 11, pp. 1573–1581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. D. J. An, W. Kim, H. P. Sang et al., “The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension,” Korean Circulation Journal, vol. 39, no. 5, pp. 180–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Blessing, M. Preusch, R. Kranzhöfer et al., “Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice,” Atherosclerosis, vol. 199, no. 2, pp. 295–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Fukuda, S. Enomoto, Y. Hirata, R. Nagai, and M. Sata, “The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice,” Biomedicine & Pharmacotherapy, vol. 64, no. 10, pp. 712–717, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Ichihara, Y. Kaneshiro, T. Takemitsu, and M. Sakoda, “Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients,” Journal of Human Hypertension, vol. 20, no. 10, pp. 787–794, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Zhang, D. Agnoletti, M. E. Safar, and J. Blacher, “Effect of antihypertensive agents on blood pressure variability: The natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study,” Hypertension, vol. 58, no. 2, pp. 155–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Sueta, N. Koibuchi, Y. Hasegawa et al., “Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity,” American Journal of Hypertension, vol. 27, no. 12, pp. 1464–1471, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. C. A. Silagy, J. J. McNeil, and B. P. McGrath, “Sample size requirements for clinical trials of isolated systolic hypertension,” Clinical and Experimental Pharmacology and Physiology, vol. 19, no. 5, pp. 294–296, 1992. View at Publisher · View at Google Scholar · View at Scopus